Literature DB >> 24630637

[The French mesothelioma network from 1998 to 2013].

Françoise Galateau-Sallé1, A Gilg Soit Ilg2, N Le Stang3, P Brochard4, J C Pairon5, P Astoul6, C Frenay6, G Blaizot7, S Chamming's5, S Ducamp2, T Rousvoal7, A de Quillacq7, V Abonnet7, I Abdalsamad7, H Begueret7, E Brambilla7, F Capron7, M C Copin7, C Danel7, A Y de Lajartre7, A Foulet-Roge7, L Garbe7, O Groussard7, S Giusiano7, V Hofman7, S Lantuejoul7, J M Piquenot7, I Rouquette7, C Sagan7, F Thivolet-Bejui7, J M Vignaud7, A Scherpereel8, M C Jaurand9, D Jean9, P Hainaut10, L Chérié-Challine2, M Goldberg2, D Luce2, E Imbernon2.   

Abstract

Mesothelioma is a rare disease less than 0.3% of cancers in France, very aggressive and resistant to the majority of conventional therapies. Asbestos exposure is nearly the only recognized cause of mesothelioma in men observed in 80% of case. In 1990, the projections based on mortality predicted a raise of incidence in mesothelioma for the next three decades. Nowadays, the diagnosis of this cancer is based on pathology, but the histological presentation frequently heterogeneous, is responsible for numerous pitfalls and major problems of early detection toward effective therapy. Facing such a diagnostic, epidemiological and medico-legal context, a national and international multidisciplinary network has been progressively set up in order to answer to epidemiological survey, translational or academic research questions. Moreover, in response to the action of the French Cancer Program (action 23.1) a network of pathologists was organized for expert pathological second opinion using a standardized procedure of certification for mesothelioma diagnosis. We describe the network organization and show the results during this last 15years period of time from 1998-2013. These results show the major impact on patient's management, and confirm the interest of this second opinion to provide accuracy of epidemiological data, quality of medico-legal acknowledgement and accuracy of clinical diagnostic for the benefit of patients. We also show the impact of these collaborative efforts for creating a high quality clinicobiological, epidemiological and therapeutic data collection for improvement of the knowledge of this dramatic disease.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Base clinicobiologique; Clinicobiological database; Diagnostic impact; Expert pathological second opinion; Impact diagnostique; Impact médicosocial; Impact thérapeutique; Medico-legal impact; Mesothelioma; Mésothéliome; Register of cancers; Registre de cancers; Seconde lecture; Therapeutic impact

Mesh:

Year:  2014        PMID: 24630637     DOI: 10.1016/j.annpat.2014.01.009

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  9 in total

1.  Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies.

Authors:  Cyril Habougit; Béatrice Trombert-Paviot; Georgia Karpathiou; François Casteillo; Sophie Bayle-Bleuez; Pierre Fournel; Jean-Michel Vergnon; Olivier Tiffet; Michel Péoc'h; Fabien Forest
Journal:  Virchows Arch       Date:  2017-03-27       Impact factor: 4.064

2.  Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry.

Authors:  Kristin J Cummings; Michael J Becich; David J Blackley; Dennis Deapen; Robert Harrison; Raffit Hassan; S Jane Henley; Mary Hesdorffer; D Kevin Horton; Jacek M Mazurek; Harvey I Pass; Emanuela Taioli; Xiao-Cheng Wu; Marjorie G Zauderer; David N Weissman
Journal:  Am J Ind Med       Date:  2019-11-19       Impact factor: 2.214

3.  Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.

Authors:  Nicolas Alcala; Lise Mangiante; Nolwenn Le-Stang; Corinne E Gustafson; Sandrine Boyault; Francesca Damiola; Karine Alcala; Marie Brevet; Françoise Thivolet-Bejui; Cécile Blanc-Fournier; Jean-Philippe Le Rochais; Gaëtane Planchard; Nathalie Rousseau; Diane Damotte; Jean Claude Pairon; Marie Christine Copin; Arnaud Scherpereel; Eric Wasielewski; Laurence Wicquart; Stéphanie Lacomme; Jean-Michel Vignaud; Gaspard Ancelin; Cécile Girard; Christine Sagan; Christelle Bonnetaud; Véronique Hofman; Paul Hofman; Jérôme Mouroux; Vincent Thomas de Montpreville; Estelle Clermont-Taranchon; Julien Mazieres; Isabelle Rouquette; Hugues Begueret; Jean-Yves Blay; Sylvie Lantuejoul; Raphael Bueno; Christophe Caux; Nicolas Girard; James D McKay; Matthieu Foll; Françoise Galateau-Salle; Lynnette Fernandez-Cuesta
Journal:  EBioMedicine       Date:  2019-10-21       Impact factor: 8.143

4.  Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).

Authors:  C Raynaud; L Greillier; J Mazieres; I Monnet; B Mastroianni; G Robinet; G Fraboulet; A Dixmier; H Berard; R Lamy; J Letreut; H Lena; G Oliviero; S Botta; A Vergnenegre; I Borget; C Chouaid
Journal:  BMC Cancer       Date:  2015-11-06       Impact factor: 4.430

5.  Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.

Authors:  Christos Chouaid; Jean Baptiste Assié; Pascal Andujar; Cecile Blein; Charlène Tournier; Alexandre Vainchtock; Arnaud Scherpereel; Isabelle Monnet; Jean Claude Pairon
Journal:  Cancer Med       Date:  2018-02-26       Impact factor: 4.452

6.  Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Authors:  Kevin Washetine; Simon Heeke; Christelle Bonnetaud; Mehdi Kara-Borni; Marius Ilié; Sandra Lassalle; Catherine Butori; Elodie Long-Mira; Charles Hugo Marquette; Charlotte Cohen; Jérôme Mouroux; Eric Selva; Virginie Tanga; Coraline Bence; Jean-Marc Félix; Loic Gazoppi; Taycir Skhiri; Emmanuelle Gormally; Pascal Boucher; Bruno Clément; Georges Dagher; Véronique Hofman; Paul Hofman
Journal:  Cancers (Basel)       Date:  2018-06-29       Impact factor: 6.639

7.  Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.

Authors:  Lisa Quetel; Clément Meiller; Jean-Baptiste Assié; Yuna Blum; Sandrine Imbeaud; François Montagne; Robin Tranchant; Julien de Wolf; Stefano Caruso; Marie-Christine Copin; Véronique Hofman; Laure Gibault; Cécile Badoual; Ecaterina Pintilie; Paul Hofman; Isabelle Monnet; Arnaud Scherpereel; Françoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Marie-Claude Jaurand; Didier Jean
Journal:  Mol Oncol       Date:  2020-03-10       Impact factor: 6.603

Review 8.  Asbestos in High-Risk Communities: Public Health Implications.

Authors:  Edward A Emmett
Journal:  Int J Environ Res Public Health       Date:  2021-02-07       Impact factor: 3.390

9.  Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma.

Authors:  Clément Meiller; François Montagne; Theo Z Hirsch; Stefano Caruso; Julien de Wolf; Quentin Bayard; Jean-Baptiste Assié; Léa Meunier; Yuna Blum; Lisa Quetel; Laure Gibault; Ecaterina Pintilie; Cécile Badoual; Sarah Humez; Françoise Galateau-Sallé; Marie-Christine Copin; Eric Letouzé; Arnaud Scherpereel; Jessica Zucman-Rossi; Françoise Le Pimpec-Barthes; Marie-Claude Jaurand; Didier Jean
Journal:  Genome Med       Date:  2021-07-14       Impact factor: 11.117

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.